Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 6/20 | 0.50 |
| ▸ | MAPT | P10636 | 6/20 | 0.47 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.46 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.45 |
| ▸ | NPC1 | O15118 | 4/20 | 0.45 |
| ▸ | RAB9A | P51151 | 4/20 | 0.45 |
| ▸ | HPGD | P15428 | 4/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | IDE | P14735 | 1/20 | 0.45 |
| ▸ | GFER | P55789 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19848311 | 0.88 | ALDH1A1 (0.50) | FGFR1MAPTPDE4BPDE4DKDM4E | |
| SCHEMBL21991654 | 0.88 | ALDH1A1 (0.50) | FGFR1MAPTPDE4BPDE4DKDM4E | |
| SCHEMBL18937429 | 0.84 | FGFR1 (0.55) | FGFR1MAPTPDE4BPDE4DKDM4E | |
| SCHEMBL5952386 | 0.84 | FGFR1 (0.49) | FGFR1MAPTKDM4EALDH1A1NPC1 | |
| SCHEMBL5951859 | 0.82 | FGFR1 (0.52) | FGFR1MAPTKDM4EALDH1A1NPC1 | |
| SCHEMBL4700068 | 0.81 | FGFR1 (0.49) | FGFR1MAPTKDM4EALDH1A1NPC1 | |
| SCHEMBL18250714 | 0.80 | RAB9A (0.52) | FGFR1MAPTKDM4EALDH1A1NPC1 | |
| SCHEMBL18250299 | 0.79 | RAB9A (0.45) | MAPTKDM4EALDH1A1NPC1RAB9A | |
| SCHEMBL19848179 | 0.79 | HCAR3 (0.42) | MAPTKDM4EALDH1A1NPC1RAB9A | |
| SCHEMBL19911407 | 0.79 | MAPT (0.50) | FGFR1MAPTKDM4EALDH1A1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10756394-B2 | Nonaqueous electrolyte and nonaqueous secondary battery | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2020-08-25 | — | — | US | disclosed |
| EP-3467930-A1 | NONAQUEOUS ELECTROLYTE AND NONAQUEOUS SECONDARY BATTERY | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2019-04-10 | — | — | EP | disclosed |
| US-20180062213-A1 | Nonaqueous Electrolyte and Nonaqueous Secondary Battery | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2018-03-01 | — | — | US | disclosed |
| US-20180062213-A1 | Nonaqueous Electrolyte and Nonaqueous Secondary Battery | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2018-03-01 | — | — | US | disclosed |
| EP-3279997-A1 | NONAQUEOUS ELECTROLYTE AND NONAQUEOUS SECONDARY BATTERY | Asahi Kasei Kabushiki Kaisha (JP) | 2018-02-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10756394-B2 | Nonaqueous electrolyte and nonaqueous secondary battery | BPTF, BRD4, KCNN2 | FGFR1 1543/4885MAPT 1283/4885PDE4B 2961/4885 |
| US-20180062213-A1 | Nonaqueous Electrolyte and Nonaqueous Secondary Battery | BPTF, BRD4, KCNN2 | FGFR1 1543/4885MAPT 1283/4885PDE4B 2961/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.